Clinical trial
Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
NCT00093613 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00093613 |
|---|---|
| Title | Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma |
| Official title | A Phase I Trial of BAY 43-9006 for Patients With Recurrent or Progressive Malignant Glioma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor |
| Intervention type | Drug, Other |
| Interventions | sorafenib tosylate, pharmacological study |
| Enrollment | 47 |
| Start date | Dec 1, 2004 |
| Primary completion | Oct 1, 2010 |
| Completion | Dec 1, 2011 |
| First posted | Oct 8, 2004 |
| Last update posted | May 30, 2014 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: